182 related articles for article (PubMed ID: 26866810)
41. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
42. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
Love RR
J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
[No Abstract] [Full Text] [Related]
43. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
44. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström K; Rydén L; Anagnostaki L; Nordenskjöld B; Stål O; Thorstenson S; Chebil G; Jönsson PE; Fernö M; Landberg G
J Clin Pathol; 2005 Nov; 58(11):1135-42. PubMed ID: 16254100
[TBL] [Abstract][Full Text] [Related]
45. Ovarian ablation as a treatment for breast cancer.
Sainsbury R
Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
[TBL] [Abstract][Full Text] [Related]
46. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
47. Ovarian ablation for premenopausal early-stage breast cancer: an update.
Celio L; Bajetta E; Toffolatti L; Catena L; Beretta E; Buzzoni R
Tumori; 2000; 86(3):191-4. PubMed ID: 10939596
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
49. Long-term consequences of ovarian ablation for premenopausal breast cancer.
Kwon JS; Pansegrau G; Nourmoussavi M; Hammond G; Carey MS
Breast Cancer Res Treat; 2016 Jun; 157(3):565-73. PubMed ID: 27236562
[TBL] [Abstract][Full Text] [Related]
50. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
51. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
52. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
53. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
54. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
55. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival.
Collichio F; Pandya K
Oncology (Williston Park); 1994 Dec; 8(12):45-52. PubMed ID: 7888312
[TBL] [Abstract][Full Text] [Related]
56. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
Hill N; Madarnas Y
Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
[TBL] [Abstract][Full Text] [Related]
57. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
58. Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
Bilimoria MM; Jordan VC
Semin Surg Oncol; 1996; 12(5):339-45. PubMed ID: 8873322
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant endocrine treatment in premenopausal early breast cancer.
Orlando L; Fedele P; Cinefra M; Sponziello F; Calvani N; Chetrì MC; Rizzo P; D'Amico M; Schiavone P; Portaluri M; Criscuolo M; Burlizzi S; Cinieri S
Oncology; 2009; 77 Suppl 1():9-13. PubMed ID: 20130426
[TBL] [Abstract][Full Text] [Related]
60. Ovarian suppression for breast cancer: an effective treatment in search of a home.
Krop IE; Winer EP
J Clin Oncol; 2005 Sep; 23(25):5869-72. PubMed ID: 16087947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]